Search Results

You are looking at 1 - 4 of 4 items for

  • Author or Editor: Robert A. Green x
  • Refine by Access: All Content x
Clear All Modify Search


To determine the prevalence of abnormalities of in vitro prothrombin time (PT) and activated partial thromboplastin time (APTT), or antithrombin III (ATIII) activity or all 3 variables in cats; and the association of abnormalities of these variables with naturally developing diseases or disorders.


Retrospective study.


85 cats from which blood had been obtained for measurement of a coagulation profile (PT, APTT, and ATIII activity) and concentration of fibrin degradation products.


Medical records from the Texas A&M College of Veterinary Medicine were reviewed to determine clinical diagnosis, results of CBC and coagulation profile, and clinical evidence of abnormal bleeding or thrombotic disease.


38 cats had one or more abnormality in the coagulation profile; most had multiple abnormalities. Twenty of these 38 cats had concurrent thrombocytopenia. Thrombocytopenia was identified in 9 of 47 cats in which results of the coagulation profile were normal. Most cats did not have clinical evidence of a coagulation disorder, and testing had been requested as part of a diagnostic work-up or before surgery. Diseases commonly associated with laboratory evidence of a coagulation disorder, either singly or in combination, included hepatic disease, neoplasia, and systemic infections.

Clinical Implications

On the basis of laboratory evidence, hemostatic disorders develop more commonly in cats than clinical signs would suggest. Coagulation profiles may be warranted in high-risk cats to alert clinicians to potential problems. (J Am Vet Med Assoc 1998;213:1290-1295)

Free access
in Journal of the American Veterinary Medical Association


Ten healthy dogs and 10 dogs with multicentric lymphoma were given a single dose of l-asparaginase at a rate of 10,000 IU/m2 of body surface. Assessment of concentrations of contributors to the coagulation process and of the ability to coagulate including antithrombin III, one-stage prothrombin time, prothrombin-proconvertin time, activated partial thromboplastin time, plasminogen, fibrinogen, and platelet number were performed prior to drug administration (day 0). These tests were repeated 24 hours (day 1), 48 hours (day 2), and 7 days after treatment with l-asparaginase. Antithrombin-III concentrations were significantly lower in the dogs with lymphoma than in healthy dogs on days 0, 1, 2, and 7; however, with the exception of day 1, mean values remained within normal limits. There was also a difference between the 2 groups in prothrombin/proconvertin values on day 7 and in platelet number on day 2, with the lymphoma group having significantly shorter prothrombin/proconvertin time than healthy dogs, and the difference in platelet numbers being associated with increased counts in the healthy dogs. Data obtained from the healthy dogs and dogs with lymphoma for each coagulation test were pooled for each treatment day (0, 1, 2, and 7), and day-0 values for each coagulation test were compared with data obtained on days 1, 2, and 7. Antithrombin-III concentration on day 7 was significantly lower than on day 0, prothrombin/ proconvertin time on day 1 was significantly longer than on day 0, and fibrinogen concentrations on days 1 and 2 were significantly lower than on day 0. Evidence of clinical hemorrhage or thrombosis was not found in any dog subsequent to l-asparaginase administration. Results of this study suggest that although individual coagulation test results may be altered, a single dose of l-asparaginase does not clinically alter coagulation in either healthy dogs or dogs with multicentric lymphoma.

Free access
in American Journal of Veterinary Research